Kombiglyze XR (Saxagliptin HCl/Metformin HCl) Patent Expiration, LOE Window & CMS Spending
Kombiglyze XR (Saxagliptin HCl/Metformin HCl) by AstraZeneca: FDA Orange Book LOE 2027-10-11, 2 AB generics, $2.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N200678 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-10-11 |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $2.2M |
| 2024 Medicare Part D Spend | $1.6M |
| 2024 Medicaid Spend | $660K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.